Tolerance development in cow’s milk–allergic infants receiving amino acid–based formula: A randomized controlled trial

Формирование толерантности у младенцев с аллергией на белок коровьего молока, получающих смесь на основе аминокислот: рандомизированное контролируемое исследование
Jan Knol, Johan Garssen, Antonella Maria Muraro, Karen Knipping, Kirsten Beyer, Diego Giampietro Peroni, Anna H Nowak-Wegrzyn, Carla McGuire Davis, Adam Tobias Fox, Marleen T. J. van Ampting, Manon M. Oude Nijhuis, Lucien F. Harthoorn, Louise Jane Michaelis, Suwat Benjaponpitak, Pantipa Chatchatee, Lars Lange, Kok Wee Chong, Pasuree Sangsupawanich, Jane E. Langford, Valérie Trendelenburg, Robert D. Pesek, Michel Erlewyn‐Lajeunesse, Lee Noimark, Gary Stiefel, Uwe Schauer, Hamelman, Boner
2021-07-02

IgE-mediated food allergyamino acid-based formulacow's milk allergydouble-blind food challengesynbiotics
BACKGROUND: Tolerance development is an important clinical outcome for infants with cow's milk allergy. OBJECTIVE: This multicenter, prospective, randomized, double-blind, controlled clinical study (NTR3725) evaluated tolerance development to cow's milk (CM) and safety of an amino acid-based formula (AAF) including synbiotics (AAF-S) comprising prebiotic oligosaccharides (oligofructose, inulin) and probiotic Bifidobacterium breve M-16V in infants with confirmed IgE-mediated CM allergy. METHODS: Subjects aged ≤13 months with IgE-mediated CM allergy were randomized to receive AAF-S (n = 80) or AAF (n = 89) for 12 months. Stratification was based on CM skin prick test wheal size and study site. After 12 and 24 months, CM tolerance was evaluated by double-blind, placebo-controlled food challenge. A logistic regression model used the all-subjects randomized data set. RESULTS: At baseline, mean ± SD age was 9.36 ± 2.53 months. At 12 and 24 months, respectively, 49% and 62% of subjects were CM tolerant (AAF-S 45% and 64%; AAF 52% and 59%), and not differ significantly between groups. During the 12-month intervention, the number of subjects reporting at least 1 adverse event did not significantly differ between groups; however, fewer subjects required hospitalization due to serious adverse events categorized as infections in the AAF-S versus AAF group (9% vs 20%; P = .036). CONCLUSIONS: After 12 and 24 months, CM tolerance was not different between groups and was in line with natural outgrowth. Results suggest that during the intervention, fewer subjects receiving AAF-S required hospitalization due to infections.
1
A multicenter randomized double-blind trial compared amino acid-based formula with synbiotics (AAF-S) versus standard AAF in IgE-mediated cow’s milk-allergic infants.
2
Cow’s milk tolerance was achieved by 49% of infants after 12 months and 62% after 24 months, with no significant difference between AAF-S and AAF.
3
Overall adverse-event rates did not differ significantly, but infection-related hospitalization was lower with AAF-S than AAF (9% vs 20%; P = .036).
4
Tolerance development after both interventions was consistent with the expected natural outgrowth of cow’s milk allergy.
5
Tolerance rates were 45% versus 52% at 12 months and 64% versus 59% at 24 months for AAF-S and AAF, respectively.

Infants with confirmed IgE-mediated cow’s milk allergy receiving amino acid–based formula with or without synbiotics

Development of cow’s milk tolerance and safety outcomes, including infection-related hospitalization, during formula intervention

Publication Details
Publication Date
2021-07-02
Journal
Publisher
ISSN
Cited by
48
Access Type
Author Information
Authors
Jan Knol
Johan Garssen
Antonella Maria Muraro
Karen Knipping
Kirsten Beyer
Diego Giampietro Peroni
Anna H Nowak-Wegrzyn
Carla McGuire Davis
Adam Tobias Fox
Marleen T. J. van Ampting
Manon M. Oude Nijhuis
Lucien F. Harthoorn
Louise Jane Michaelis
Suwat Benjaponpitak
Pantipa Chatchatee
Lars Lange
Kok Wee Chong
Pasuree Sangsupawanich
Jane E. Langford
Valérie Trendelenburg
Robert D. Pesek
Michel Erlewyn‐Lajeunesse
Lee Noimark
Gary Stiefel
Uwe Schauer
Hamelman
Boner
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%